Back to top
more

BeiGene (BGNE)

(Delayed Data from NSDQ)

$164.44 USD

164.44
220,950

+3.88 (2.42%)

Updated May 8, 2024 04:00 PM ET

After-Market: $164.34 -0.10 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

by Zacks Equity Research

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA

by Zacks Equity Research

The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.

BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion

by Zacks Equity Research

The FDA approves BeiGene's (BGNE) Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia. This marks the second approval for the drug in the United States.

Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers

by Zacks Equity Research

Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.

Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes

by Zacks Equity Research

Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.

Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook

by Zacks Equity Research

Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.

BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China

by Zacks Equity Research

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene

by Zacks Equity Research

Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.

All You Need to Know About BeiGene, Ltd. (BGNE) Rating Upgrade to Buy

by Zacks Equity Research

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Indrajit Bandyopadhyay headshot

4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes

by Indrajit Bandyopadhyay

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

BeiGene's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in BeiGene.

Amgen's New Kyprolis Combo Gets FDA Nod for Multiple Myeloma

by Zacks Equity Research

Amgen's (AMGN) Kyprolis gets FDA approval for label expansion as second to fourth-line treatment for relapsed/refractory multiple myeloma in combination with J&J's Darzalex and dexamethasone.

What Makes BeiGene, Ltd. (BGNE) a New Buy Stock

by Zacks Equity Research

BeiGene, Ltd. (BGNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

BeiGene (BGNE) in Focus: Stock Moves 8.7% Higher

by Zacks Equity Research

BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Amgen (AMGN) Invests Further in China-Based Oncology Partner

by Zacks Equity Research

Amgen (AMGN) announces additional investment of approximately $421 million in BeiGene. The companies have a collaboration for oncology products signed in 2019.

Leap Therapeutics Surges on License Agreement With BieGene

by Zacks Equity Research

Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.

BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China

by Zacks Equity Research

BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.

The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill

AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

by Zacks Equity Research

AMAG disappoints investors with earnings and sales miss in the third quarter.

4 Stocks to Buy From Sectors With Maximum Job Gains

by Zacks Equity Research

The American jobs' market added new positions in October at a better-than-expected pace. Here's how to make the most of it.

Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance

by Zacks Equity Research

Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

BeiGene, Ltd. (BGNE) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Reata Successfully Completes Neuromuscular Disorder Study

by Zacks Equity Research

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA

by Zacks Equity Research

The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.